Intermediate-Dose Enoxaparin After Cardiac Ablation Procedures

Journal Title: Journal of Hypertension and Cardiology - Year 2014, Vol 1, Issue 3

Abstract

Objective: Ablation of foci within the atria has been shown to resolve symptoms of atrial fibrillation and atrial flutter. However, no standard has been established for anticoagulation after the procedure. Enoxaparin has been well described in the literature as a means to provide anticoagulation after ablation procedures. The only enoxaparin doses previously studied were 0.5 mg/kg and 1 mg/kg, both given every 12 hours. The purpose of the study was to compare the incidence of a major bleed or vascular complication in patients who received enoxaparin doses between 0.5 mg/kg and 1 mg/kg every 12 hours with patients who received either 0.5 mg/kg or 1 mg/kg every 12 hours. Methods: This IRB-approved, single-center, retrospective, cohort study included subjects greater than 18 years of age who received an atrial fibrillation or atrial flutter ablation procedure and at least one dose of enoxaparin post-ablation. Results: There were 119 subjects who satisfied the inclusion criteria. The primary outcome, incidence of major bleeding or vascular complication, did not demonstrate a statistically significant difference between groups (p = 0.92). The incidences were 4.8% with enoxaparin ≥ 1 mg/kg, 3% with enoxaparin between 0.5 mg/kg and 1 mg/kg, and 3.2% with enoxaparin ≤ 0.5 mg/kg. No subject experienced an ischemic stroke or transient ischemic attack within 28 days of a cardiac ablation procedure. Conclusion: Significant increases in major bleeding or vascular complications may not exist with an intermediate dose of enoxaparin provided after a cardiac ablation procedure.

Authors and Affiliations

Drayton A. Hammond, Christina E. DeRemer, David M. Killough, Adam E. Berman

Keywords

Related Articles

Cardiac Mechanics in Patients with Systemic Hypertension with Normal EF: A Speckle - Strain Imaging Study

Background: Conventional transthoracic echocardiography (TTE) and tissue Doppler imaging (TDI) are usually unable to reveal very early subtle abnormalities in left ventricular (LV) systolic function caused by hypertensi...

A Potential New Technique to Estimate the Origins of Focal Atrial Tachycardias from 12-Lead Electrocardiograms

Background: This brief report presents a potential new technique for locating the sites of origin of focal atrial tachycardias from standard 12-lead electrocardiograms. Methods: Estimated P wave vector coordinates are...

Single Daily Activity or Exercise Capacity Measurements Did not Predict Future Changes in Cardiovascular Risk Factors in Congenital Heart Disease

Objective: Studies suggest that cardiovascular risk of patients with congenital heart disease (CHD) is increased. This study aims on the predictive value of a single daily activity and exercise capacity assessments on th...

Analysis of Effects of Kale Powder Consumption among Subjects with Potential Metabolic Syndrome: A Prospective Single-Arm Clinical Study

Objective: The prospective intervention study was conducted to investigate the effects of kale powder (Kale juice mixed with water or milk) consumption on metabolic syndrome in subjects with potential metabolic syndrome...

Intercoronary Continuity with Bidirectional Flow: Dynamic Changes Parallel to Coronary Disease Progression

Direct intercoronary continuity is a rare angiographic finding. We report an unusual case of a 51-year old male with coronary disease who demonstrated intermittent variability in the directions of flow as a result of cha...

Download PDF file
  • EP ID EP279572
  • DOI 10.14302/issn.2329-9487.jhc-13-313
  • Views 106
  • Downloads 0

How To Cite

Drayton A. Hammond, Christina E. DeRemer, David M. Killough, Adam E. Berman (2014). Intermediate-Dose Enoxaparin After Cardiac Ablation Procedures. Journal of Hypertension and Cardiology, 1(3), 22-29. https://europub.co.uk/articles/-A-279572